Hu Shengshou

Research areas: Surgical treatment of complex congenital heart disease; application of cell therapy and tissue engineering techniques in cardiovascular diseases; development of artificial hearts and ventricular assist devices; immunological principles of allogeneic and xenogeneic heart transplantation; immune activation to promote myocardial regeneration.

Cutting-edge technologies: Led the development of my country's first axial-flow pump ventricular assist device to enter clinical trials, and jointly developed my country's first fully magnetically levitated artificial heart (CH-VAD), completing the entire clinical research from animal experiments to clinical registration and evaluation. Pioneered conjoined heart transplantation in China and proposed the concept of "biological assist pump" for the treatment of end-stage coronary artery disease.

Specializes in treating: end-stage heart failure, complex congenital heart disease, and coronary heart disease.

Academic Highlights and Core Values: Academician of the Chinese Academy of Engineering, Foreign Academician of the French Academy of Medicine, Director of the National Center for Cardiovascular Diseases, President of Fuwai Hospital, Director of the National Key Laboratory of Cardiovascular Diseases, Chief Scientist of the "973 Program," and recipient of the "National Science Fund for Distinguished Young Scholars." He has received three National Science and Technology Progress Awards (Second Class), as well as numerous honors including the Ho Leung Ho Lee Foundation Science and Technology Progress Award, the National Innovation and Advancement Award, and the Guanghua Engineering Science and Technology Award. In 2012, the project he led won the National Science and Technology Progress Award (Second Class).